Clinical trial
A Randomized, Multi-center, Double-blind, Sham-controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered Rugonersen in Pediatric and Adult Participants With Angelman Syndrome
NCT07605429 is registered in ClinicalTrials.gov with OHB Pediatrics Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Multi-center, Double-blind, Sham-controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered Rugonersen in Pediatric and Adult Participants With Angelman Syndrome
- Lead sponsor
- OHB Pediatrics Ltd.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- June 23, 2026
- Completion date
- March 31, 2031
- Enrollment
- 165 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.